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A B S T R A C T
In this study, we aimed to investigate the immunogenicity of cationic liposomes loaded with diphtheria toxoid
(DT) and poly(I:C) after hollow microneedle-mediated intradermal vaccination in mice. The following liposomal
formulations were studied: DT loaded liposomes, a mixture of free DT and poly(I:C)-loaded liposomes, a mixture
of DT-loaded liposomes and free poly(I:C), and liposomal formulations with DT and poly(I:C) either individually
or co-encapsulated in the liposomes. Reference groups were DT solution adjuvanted with or without poly(I:C)
(DT/poly(I:C)). The liposomal formulations were characterized in terms of particle size, zeta potential, loading
and release of DT and poly(I:C). After intradermal injection of BALB/c mice with the formulations through a
hollow microneedle, the immunogenicity was assessed by DT-speciﬁc ELISAs. All formulations induced similar
total IgG and IgG1 titers. However, all the liposomal groups containing both DT and poly(I:C) showed enhanced
IgG2a titers compared to DT/poly(I:C) solution, indicating that the immune response was skewed towards a Th1
direction. This enhancement was similar for all liposomal groups that contain both DT and poly(I:C) in the
formulations. Our results reveal that a mixture of DT encapsulated liposomes and poly(I:C) encapsulated lipo-
somes have a similar eﬀect on the antibody responses as DT and poly(I:C) co-encapsulated liposomes. These
ﬁndings may have implications for future design of liposomal vaccine delivery systems.
1. Introduction
Vaccination has become the most eﬀective method for preventing
infectious diseases, having led to the eradication of smallpox and severe
restriction of other devastating diseases such as polio and measles
(Jiang et al., 2017; Peek et al., 2008). However, there is still a need for
new and better vaccines against emerging infectious diseases (Rappuoli
et al., 2014). Nowadays, vaccination gains increasing attention also for
therapeutic use against established diseases such as cancer and chronic
auto-immune disorders (Melief et al., 2015). Most vaccines are deliv-
ered by intramuscular or subcutaneous injection. However, these in-
jections need special training and can cause pain (Kim et al., 2012). To
avoid the drawbacks of the hypodermic needles, microneedles have
been developed. Microneedles are micro-sized needle structures with a
length shorter than 1mm and can be used to penetrate skin barrier in a
non-invasive and pain-free way (Larraneta et al., 2016; Tuan-Mahmood
et al., 2013; van der Maaden et al., 2012). Owing to the large number of
antigen presenting cells in viable dermis and epidermis, dose-sparing
may be achieved (Li et al., 2011).
Traditional vaccines are derived from attenuated organisms or in-
activated pathogens and toxins. Attenuated vaccines have safety con-
cerns as they may revert back to their virulent form (Reed et al., 2013).
Inactivated vaccines like subunit antigens are safer but they are gen-
erally less immunogenic (Peek et al., 2008; Reed et al., 2013). To en-
hance and modify the immune response, immune modulators or na-
noparticle delivery systems can be used (Zhao et al., 2014).
Ligands for toll-like receptors (TLRs) can be used as immune mod-
ulators to enhance the immune response against antigens by acting as a
danger signal to the antigen-presenting cells. Among diﬀerent types of
TLR ligands, poly(I:C), which is a virus-associated double-stranded
RNA, has been extensively investigated (Ammi et al., 2015). Poly(I:C) is
a ligand for TLR3, which is located in the membrane of the endosomal
compartments of dendritic cells. Previously, it was shown that com-
pared to other TLR agonists, poly(I:C) induced a more eﬀective IFN-γ
secretion, which is an important linker of innate and adaptive immunity
(Longhi et al., 2009). Furthermore, poly(I:C) has been shown to en-
hance anti-tumor immune responses and facilitate tumor elimination
(Ammi et al., 2015).
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Nanoparticles have been shown to improve the immunogenicity of
antigens by protecting the antigens from degradation, increasing their
uptake by antigen-presenting cells and co-delivering antigens and im-
mune modulators (Fan and Moon, 2015). Among diﬀerent types of
nanoparticle delivery systems, liposomes have been studied frequently
because of their excellent biocompatibility and biodegradability
(Giddam et al., 2012). Studies have shown that co-formulating antigen
and TLR ligands in liposomes can enhance Th1 and CD8+ T cell re-
sponses compared to mixture of antigen and adjuvant after intradermal
vaccination. Some studies have shown that co-encapsulation of OVA
with poly(I:C) or CpG in cationic liposomes signiﬁcantly increased the
IgG2a response (Th1 type) and the CD8+ T cell response compared to
OVA and adjuvant solutions (Bal et al., 2011; Du et al., 2017; Guo et al.,
2013). Other studies have shown that peptide and poly(I:C) loaded
cationic liposomes induced potent Th1 and CD8+ T cell responses
needed for tumor vaccination (Varypataki et al., 2017; Varypataki
et al., 2015). These results are noteworthy, as nowadays there is an
increasing need for potent cellular immune responses, e.g., for im-
munotherapy of cancer (Ammi et al., 2015; Fan and Moon, 2015;
Hamdy et al., 2008) and intracellular pathogens (Chong et al., 2005;
Zaric et al., 2013). However, it is not yet well understood whether the
antigen and immune modulator need to be co-encapsulated in lipo-
somes, or they can similarly modulate the immune response when en-
capsulated individually in liposomes. Therefore, the aim of this study
was to examine whether co-encapsulation of antigen and adjuvant is
required for enhancing and modulating the immune response.
In the present study, we chose diphtheria toxoid (DT) as a model
antigen and studied the eﬀect of encapsulation of DT and poly(I:C) in
liposomes on immune responses in mice after hollow microneedle
mediated intradermal immunization. DT and poly(I:C) were either in-
dividually encapsulated or co-encapsulated in 1,2-dioleoyl-3-trimethy-
lammonium-propane chloride (DOTAP) based cationic liposomes. To
investigate the modulation of immune responses by the liposomal for-
mulations, IgG1 and IgG2a titers, which are indications of a Th2 and a
Th1 type immune response, respectively (Maassen et al., 2003), were
determined.
2. Materials and methods
2.1. Materials
DT (batch 04–44, 1 µg equal to 0.3 Lf) and diphtheria toxin were
provided by Intravacc (Bilthoven, The Netherlands). Aluminum phos-
phate was purchased from Brenntag (Ballerup, Denmark). Egg phos-
phatidylcholine (EggPC), DOTAP and 1,2-dioleoyl-sn-glycero-3-phos-
phoethanolamine (DOPE) were ordered from Avanti Polar Lipids
(Alabaster, AL). Polyinosinic-polycytidylic acid (poly(I:C)) (low mole-
cular weight) and its rhodamine-labeled version were purchased from
Invivogen (Toulouse, France). Foetal bovine serum (FBS), M199
medium (with Hanks’ salts and L-glutamin), bovine serum albumin
(BSA) and hydroﬂuoric acid ≥48% were ordered from Sigma-Aldrich
(Zwijndrecht, The Netherlands). Glucose solution, L-Glutamine
(200mM), penicillin–streptomycin (10,000 U/ml) and 1-stepTM ultra
3,3′,5,5′-tetramethylbenzidine (TMB) were obtained from Thermo-
Fisher Scientiﬁc (Waltham, MA). HRP-conjugated goat anti-mouse total
IgG, IgG1 and IgG2a were purchased from Southern Biotech
(Birmingham, AL). Sulfuric acid (95–98%) was obtained from JT Baker
(Deventer, The Netherlands). VivaSpin 2 and 500 centrifugal con-
centrators (PES membrane, MWCO 1000 kDa) were obtained from
Sartorius Stedim (Nieuwegein, The Netherlands). Sterile phosphate
buﬀered saline (PBS, 163.9 mM Na+, 140.3 mM Cl-, 8.7 mM HPO42−,
1.8 mM H2PO4-, pH 7.4) was obtained from Braun (Oss, The
Netherlands). 10 mM PB (7.7mM Na2HPO4, 2.3 mM NaH2PO4, pH 7.4)
was prepared in the laboratory. All the other chemicals used were of
analytical grade and Milli-Q water (18MΩ/cm, Millipore Co.) was used
for the preparation of all solutions.
2.2. Preparation of liposomes
Liposomes were prepared by thin-ﬁlm hydration followed by ex-
trusion, as reported earlier (Varypataki et al., 2016). EggPC (25mg/
ml), DOPE (25mg/ml) and DOTAP (25mg/ml) in chloroform were
mixed in a molar ratio of 9:1:2.5 in a round bottom ﬂask. The organic
solvent was evaporated by using a rotary evaporator (Buchi rotavapor
R210, Flawil, Switzerland) for 1 h at 40 °C and 120 rpm. To prepare DT
encapsulated liposomes (Lipo-DT), the lipid ﬁlm was hydrated with
0.25mg/ml DT dissolved in 10mMPB (pH 7.4) by vortexing for 10 s,
resulting in a 12.5 mg/ml lipid suspension. To prepare poly(I:C) en-
capsulated liposomes (Lipo-PIC), the lipid ﬁlm was hydrated with
0.25mg/ml poly(I:C) solution (containing 0.5% (w/w) rhodamine-la-
beled poly(I:C)). To prepare DT and poly(I:C) co-encapsulated lipo-
somes (Lipo-DT-PIC), after lipid ﬁlm hydration with DT solution,
0.25mg/ml poly(I:C) (containing 0.5% (w/w) rhodamine-labeled poly
(I:C)) dissolved in 10mM PB (pH 7.4) was added slowly (2 µl/min) into
the lipid suspension by using a syringe pump (NE-300, Prosense, Oos-
terhout, The Netherlands). Next, the lipid vesicles were extruded (LI-
PEXTM extruder, Northern Lipids, Burnaby, Canada) four times through
a carbonate ﬁlter with a pore size of 400 nm and another four times
through a ﬁlter with a pore size of 200 nm (Nucleopore Millipore,
Amsterdam, The Netherlands). To remove the DT/poly(I:C) not asso-
ciated with liposomes, the suspension was transferred into VivaSpin 2
centrifugal concentrators (1000 kDa MWCO) and centrifuged (Allegra
X-12R, Beckman Coulter, Indianapolis, IN) for 6 h (350g, 22 °C). Finally,
the liposomes were washed with 10mM PB and kept at 4 °C in the re-
frigerator prior to use. The ﬁltrates, containing the free DT/poly(I:C),
were collected for determination of loading eﬃciency of DT and poly
(I:C).
2.3. Characterization of liposomal formulations
2.3.1. Particle size and zeta potential measurements
The particle size of the liposomes was measured by dynamic light
scattering by using a Nano ZS® zetasizer (Malvern Instruments,
Worcestershire, U.K.). The zeta potential of liposomes was measured by
the same instrument by using laser Doppler velocimetry. The liposomes
were diluted with 10mM PB (pH 7.4) to a concentration of 25 µg/ml for
the measurements. The samples were measured 3 times with 10 runs for
each measurement.
2.3.2. Determination of encapsulation eﬃciency (EE) and loading capacity
(LC) of DT/poly(I:C) in liposomes
To determine the EE and LC of DT and poly(I:C), the intrinsic
ﬂuorescence intensity of DT (λex 280 nm/λem 320 nm) and ﬂuorescence
intensity of rhodamine labeled poly(I:C) (λex 545 nm/λem 576 nm) in
the puriﬁcation ﬁltrates were measured by using a Tecan M1000 plate
reader (Männedorf, Switzerland). The EE and LC were calculated by
using Eqs. (1) and (2) as below:
= ×
M
M
EE 100%loadedDT poly I C
totalDT poly I C
/ ( : )
/ ( : ) (1)
= ×
+ +
M
M
LC 100%loadedDT poly I C
Liposomes DT poly I C
/ ( : )
( : ) (2)
where Mloaded DT/poly(I:C) represents the mass of encapsulated DT or poly
(I:C),Mtotal DT/poly(I:C) is the total amount of DT or poly(I:C) added to the
formulations and Mliposomes+DT+poly(I:C) is the total weight of liposomes,
DT and poly(I:C).
2.3.3. In vitro release of DT and poly(I:C) from liposomes
To study the in vitro release of DT and poly(I:C) from Lipo-DT, Lipo-
PIC and Lipo-DT-PIC, the liposomes (containing about 80 µg/ml DT
with or without 80 µg/ml poly(I:C)) were dispersed in PBS and shaken
with a speed of 550 rpm at 37 °C by using an Eppendorf thermomixer
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(Nijmegen, The Netherlands). At predetermined time points, 300 µl li-
posomes were transferred into the VivaSpin 500 concentrators and
centrifuged for 30min with a speed of 350g. After the centrifugation,
fresh PBS with the same volume as the ﬁltrates was added back to the
liposomes. The concentration of DT and poly(I:C) in the ﬁltrates was
determined by measuring the intrinsic ﬂuorescence intensity of DT (λex
280 nm/λem 320 nm) and ﬂuorescence intensity of rhodamine labeled
poly(I:C) (λex 545 nm/λem 576 nm), respectively, by using a Tecan
M1000 plate reader.
2.3.4. Adsorption of free DT or poly(I:C) on liposomes loaded with the other
active ingredient
To investigate the adsorption of free DT to Lipo-PIC, DT was mixed
with Lipo-PIC in PBS, resulting in a concentration of 31 µg/ml for both
DT and poly(I:C). The samples were incubated in the Eppendorf ther-
momixer (Nijmegen, The Netherlands) at 37 °C with a speed of
300 rpm. To investigate the adsorption of free poly(I:C) to Lipo-DT, poly
(I:C) was mixed with Lipo-DT in PBS, resulting in a concentration of
31 µg/ml for both DT and poly(I:C). After 4 or 24 h, the samples were
transferred to VivaSpin 500 centrifugal concentrators (PES membrane,
1000 kDa MWCO) and centrifuged for 30min with a speed of 350g. The
DT or poly(I:C) in the ﬁltrates was quantiﬁed by measuring the intrinsic
ﬂuorescence intensity of DT (λex 280 nm/λem 320 nm) or ﬂuorescence
intensity of rhodamine labeled poly(I:C) (λex 545 nm/λem 576 nm),
respectively. The adsorption eﬃciency of DT or poly(I:C) was calcu-
lated according to Eq. (3) as follow:
⎜ ⎟= ⎛
⎝
− ⎞
⎠
×
M
M
Adsorption efficiency % 1 100%DT poly I C in filtrates
DT poly I C total
/ ( : )
/ ( : ) (3)
where MDT/poly(I:C) in ﬁltrates represents the mass of DT or poly(I:C) in
ﬁltrates after centrifugation, and MDT/poly(I:C) total is the total mass of DT
or poly(I:C) added.
2.4. Hollow microneedles and applicator
The hollow microneedles were prepared by hydroﬂuoric acid
etching of fused silica capillaries (Schipper et al., 2016; van der Maaden
et al., 2014). Brieﬂy, silica capillaries (Polymicro, Phoenix AZ, 375 μm
outer diameter, 50 μm inner diameter) were cut into 4-cm pieces and
ﬁlled with silicone oil in a vacuum oven (100 °C) overnight. The sili-
cone oil-ﬁlled capillaries were etched into hollow microneedles by
immersing their ends in ≥48% hydroﬂuoric acid for 4 h at room tem-
perature. Finally, the polyimide coating on the microneedles was re-
moved by dipping the microneedles into hot sulfuric acid (250 °C) for
5min.
To reproducibly insert hollow microneedles into mouse skin, a
hollow microneedle applicator developed in our lab was used (Schipper
et al., 2016; van der Maaden et al., 2014). The system consists of a
syringe pump (NE-300, Prosense, Oosterhout, The Netherlands) and an
injector, which were used to accurately control the injection rate
(10 µl/min), the injection volume (10 µl) and the injection depth
(120 µm). The pump, injector and hollow microneedles were connected
by using high-pressure resistant CapTiteTM connectors and silica ca-
pillaries.
2.5. Immunization study
Female BALB/c (H2d) mice were ordered from Charles Rivers
(Maastricht, The Netherlands) and accommodated under standardized
conditions in the animal facility of Leiden Academic Centre for Drug
Research, Leiden University. The immunization study was approved by
the ethical committee on animal experiments of Leiden University
(Licence number 14166).
The mice were 7–8weeks old at the beginning of the experiments.
The mice were anesthetized by intraperitoneal injection of ketamine
(60mg/kg) and xylanize (4 mg/kg) before shaving of the injection site.
The mice were then injected with 10 µl of the formulations, containing
0.31 µg DT with or without 0.31 µg poly(I:C), into abdomen skin by
using the hollow microneedle and the applicator, as described above.
The following liposomal formulations were used: DT encapsulated li-
posomes (Lipo-DT), a mixture of DT-encapsulated liposomes and free
poly(I:C) (Lipo-DT+PIC), a mixture of free DT and poly(I:C)-en-
capsulated liposomes (DT+ Lipo-PIC), a mixture of DT-encapsulated
liposomes and poly(I:C)-encapsulated liposomes (Lipo-DT+Lipo-PIC),
and DT and poly(I:C) co-encapsulated liposomes (Lipo-DT-PIC). Control
groups were injected with 0.31 µg DT with or without 0.31 µg poly(I:C)
solution (DT/poly(I:C)). All formulations were freshly prepared and
mixed prior to the immunization study. Subcutaneously injected 5 µg
DT and 150 µg aluminum phosphate (DT-Alum) was used as a positive
control. The mice were immunized on day 0, 21, 42 and sacriﬁced on
day 56. Serum was withdrawn from the tail vein of mice on day 0, 21
and 42 and the sacriﬁce serum was taken from the femoral artery on
day 56.
2.6. Determination of DT-speciﬁc IgG antibody titers
DT-speciﬁc antibodies were measured by using a sandwich enzyme-
linked immunosorbent assay (ELISA) as described earlier (Slutter et al.,
2011). The wells of 96-well plates were coated with 140 ng DT and
incubated overnight at 4 °C. The plates were blocked with 1% BSA at
37 °C for 1 h. After blocking, appropriate three-fold serial dilutions of
mouse sera were transferred into the plates and incubated for 2 h at
37 °C. The plates were then incubated with horseradish peroxidase-
conjugated goat antibodies against total IgG, IgG1 or IgG2a (1:5000
dilution) for 1.5 h at 37 °C. Subsequently, the plates were incubated
with TMB and 2M sulfuric acid was used to stop the reaction. The
absorbance was measured at 450 nm by using a Tecan M1000 plate
reader. The antibody titers were expressed as log10 value of the mid-
point of S-shaped dilution-absorbance curve of the diluted serum level.
2.7. Determination of DT-neutralizing antibodies
The functionality of the antibody response was determined by
measuring diphtheria toxin-neutralizing antibodies in a Vero cell test
(Ding et al., 2009). The serum samples were ﬁrst diluted by M199
medium supplemented with 5% FBS, 0.5% glucose, 0.8% L-glutamine
and 1% penicillin–streptomycin. Appropriate two-fold serial dilutions
of the serum were applied to 96-well plates. Next, 5× 10−5 Lf diph-
theria toxin was added to each well. Subsequently, 1.25×104 Vero
cells were added to each well and incubated for 6 days at 37 °C in 5%
CO2. Finally, the neutralizing antibodies were expressed as the log2
value of the highest serum dilution that protected the Vero cells.
2.8. Statistics analysis
All the data of antibody titers were analyzed by one way ANOVA
with Newman-Keuls Multiple post-test by using GraphPad Prism soft-
ware (version 5.02). The level of signiﬁcance was set at p < 0.05.
3. Results
3.1. Physicochemical characteristics of the liposomes and in vitro release of
DT and poly(I:C)
Lipo-DT, Lipo-PIC and Lipo-DT-PIC were ﬁrst characterized in terms
of particle size, poly dispersity index (PDI) and zeta potential. As shown
in Table 1, Lipo-DT and Lipo-PIC had a similar average size below
200 nm with a low PDI, while Lipo-DT-PIC showed a slightly larger size
and PDI. All the liposomes had a positive zeta potential above +35mV.
Both DT and poly(I:C) were eﬃciently encapsulated into the liposomes,
with a EE higher than 96%. Furthermore, DT and poly(I:C) had a
G. Du et al. International Journal of Pharmaceutics 547 (2018) 250–257
252
similar LC% of about 1.7% (Table 1).
To study the in vitro release of DT and poly(I:C), the prepared li-
posomes were incubated in PBS for one month. As shown in Fig. 1A,
there was a burst release of DT of about 25% from both Lipo-DT and
Lipo-DT-PIC within the ﬁrst day. After 3 days, almost no additional DT
was released. On day 30, the total release of DT from Lipo-DT and Lipo-
DT-PIC was about 50% and 40%, respectively. Similarly, about 20% of
the poly(I:C) was quickly released from Lipo-PIC and Lipo-DT-PIC
within the ﬁrst day and after day 3 almost no additional release was
detected (Fig. 1B). On day 30, about 40% and 25% of the loaded poly
(I:C) were released from Lipo-PIC and Lipo-DT-PIC, respectively. In
summary, after incubation in PBS for one month, less than half of the
loaded DT or poly(I:C) was released from the liposomes.
In order to study the interaction between free DT or poly(I:C) and
the positively charged liposomes loaded with the other active in-
gredient after mixing in PBS, the adsorption of DT or poly(I:C) on the
liposomes were determined. There were 75.9 ± 3.8% (mean ± SEM,
n=3) and 77.4 ± 0.8% (mean ± SEM, n=3) of DT adsorbing on the
surface of Lipo-PIC at 4 h or 24 h after mixing, respectively. In case of
poly(I:C), 95.9 ± 2.7% (mean ± SEM, n=3) and 95.6 ± 1.0%
(mean ± SEM, n=3) were adsorbed on the surface of Lipo-DT at 4 or
24 h after mixing, respectively. In summary, most of free DT or poly
(I:C) was adsorbed on the surface of liposomes after mixing.
3.2. Intradermal vaccination study
The formulations were intradermally delivered into mice by using
hollow microneedles with a DT dose of 0.31 µg with or without 0.31 µg
Table 1
Physicochemical characteristics of DT/poly(I:C) encapsulated liposomes (n= 3).
Liposomes Sizea (nm) PDIb ZPc (mV) EEd (%) LCe (%)
DT Poly(I:C) DT Poly(I:C)
Lipo-DT 182 ± 8 0.195 ± 0.012 +37 ± 1 96.5 ± 2.1 – 1.6 ± 0.1 –
Lipo-PIC 184 ± 6 0.153 ± 0.010 +37 ± 1 – 98.5 ± 0.8 – 1.7 ± 0.0
Lipo-DT-PIC 238 ± 11 0.243 ± 0.003 +35 ± 1 98.0 ± 0.8 98.9 ± 0.5 1.7 ± 0.0 1.7 ± 0.0
Data are average ± SEM of 3 independent batches.
a Size: Z-average diameter.
b PDI: poly dispersity index.
c ZP: zeta potential.
d EE: encapsulation eﬃciency.
e LC: loading capacity.
Fig. 1. In vitro release of DT and poly(I:C)
from liposomes. Lipo-DT, Lipo-PIC and Lipo-
DT-PIC were suspended in PBS at 37 °C and
shaken with a speed of 550 rpm. The release
sample was collected during one month at
diﬀerent predetermined time points to de-
termine the released amounts of DT and
poly(I:C). A: Release of DT from Lipo-DT
(spheres) and Lipo-DT-PIC (squares).
Insertion: release over a period of 1.5 days.
B: Release of poly(I:C) from Lipo-PIC
(spheres) and Lipo-DT-PIC (squares).
Insertion: release over a period of 1.5 days.
Bars represent mean ± SEM, n= 3.
Fig. 2. DT-speciﬁc total IgG titers on day 21 (A), 42 (B) and 56 (C). Mice were immunized on day 0 (prime), 21 (ﬁrst boost), 42 (second boost) and sacriﬁced on day
56. Blood serum was withdrawn from the tail vein of mice before each immunization and sacriﬁce. On day 0 there was no detectable response (data not shown). The
total IgG titers were measured by ELISA and expressed as log10 values of the mid-point of S-shaped dilution-absorbance curve of the diluted serum level. Bars
represent mean ± SEM, n=8. *p < 0.05, **p < 0.01.
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poly(I:C), based on our previous dose response study (Schipper et al.,
2017). Subcutaneously injected DT-Alum with a much higher dose (5 µg
DT and 150 µg Alum) was used as a positive control. During the in-
jection, there was no visible leakage and successful injection was in-
dicated by the formation of the bleb on the abdomen area of mouse
skin.
DT-speciﬁc total IgG and subtype titers (IgG1 and IgG2a) are pre-
sented in Figs. 2 and 3, respectively. As shown in Fig. 2, total IgG titers
increased after each immunization. As expected, DT-Alum induced
signiﬁcantly higher total IgG responses than all other formulations on
day 21 and 42 (p < 0.05) (Fig. 2A and B). However, on day 56 the
response of the intradermal groups increased to similar levels to that
induced by DT-Alum (except DT), despite the 15-fold lower dose ad-
ministered (Fig. 2C). The encapsulation of DT/poly(I:C) in liposomes
did not increase the total IgG response compared to DT/poly(I:C) so-
lutions (p > 0.05). Furthermore, the addition of poly(I:C) did not
change the total IgG response.
Next, the IgG1 and IgG2a titers were measured. As shown in Fig. 3,
the IgG1 response followed the total IgG response: liposomal formula-
tion groups induced equally strong IgG1 responses compared to DT/
poly(I:C) solutions (p > 0.05). However, when focusing on IgG2a re-
sponse, clear diﬀerences were observed among the groups. On day 21
Fig. 3. DT-speciﬁc IgG1 (A, C, E) and IgG2a (B, D, F) titers on day 21 (A, B), 42 (C, D) and 56 (E, F). Mice were immunized on day 0 (prime), 21 (ﬁrst boost), 42
(second boost) and sacriﬁced on day 56. Blood serum was withdrawn from the tail vein of mice before each immunization and sacriﬁce. On day 0 there was no
detectable response (data not shown). The IgG titers were measured by ELISA and expressed as log10 values of the mid-point of S-shaped dilution-absorbance curve
of the diluted serum level. Bars represent mean ± SEM, n=8. *p < 0.05, ***p < 0.001.
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all groups except DT-Alum developed a detectable IgG2a response
(Fig. 3B). After the 1st boost (day 42), all groups showed an IgG2a
response (Fig. 3D). Moreover, liposomal groups that contained both DT
and poly(I:C), i.e., Lipo-DT+PIC, DT+ Lipo-PIC, Lipo-DT+ Lipo-PIC
and Lipo-DT-PIC, induced a similar IgG2a response that was higher
than the response induced by DT solution (p < 0.05) and the DT and
poly(I:C) mixture (Fig. 3D), although compared with the latter the
diﬀerence is not signiﬁcant (p > 0.05). After the 2nd boost (day 56),
the IgG2a response of all groups increased to a higher level, but still the
liposomal groups containing both DT and poly(I:C) induced a distinctly
higher IgG2a response than DT solution (Fig. 3F). In summary, the re-
sults showed that the IgG2a response was enhanced when DT/poly(I:C)
was loaded in liposomes, no matter whether only one ingredient or both
of them were encapsulated in liposomes. Furthermore, DT and poly(I:C)
individually encapsulated in liposomes induced a similar IgG2a re-
sponse compared to DT and poly(I:C) co-encapsulated in liposomes. In
contrast, DT encapsulated liposomes (Lipo-DT) did not enhance the
IgG2a response compared to DT solution. Additionally, the DT-Alum
group did not improve the IgG2a response in spite of a much higher
dose.
In order to study functionality of the antibody response, the neu-
tralizing antibody titers in serum on day 56 were determined by a Vero
cell assay. The sera of the DT-Alum group contained higher levels of
toxin-neutralizing antibodies than all other groups (p < 0.05) (Fig. 4).
The liposomal groups containing both DT and poly(I:C) showed similar
neutralizing titers compared to DT/poly(I:C) solutions. The Lipo-DT
group seemed to have the lowest titers among the intradermal groups,
but the diﬀerence is not signiﬁcant. In summary, the encapsulation of
DT/poly(I:C) in liposomes did not improve the protective immunity
against diphtheria toxin.
4. Discussion
Liposome-based delivery system for vaccination has been ex-
tensively investigated (Giddam et al., 2012; Perrie et al., 2016). When
focusing on intradermal vaccination, several studies have shown that
co-encapsulation of antigen and adjuvant in liposomes can increase
IgG2a and CD8+ T cell responses (Bal et al., 2011; Boks et al., 2015; Du
et al., 2017; Guo et al., 2013; Varypataki et al., 2015). In one of our
previous studies, we used hollow microneedles to examine the eﬀect of
nano-encapsulation of OVA and poly(I:C) on the immune response in
mice after intradermal vaccination. In that study, four types of nano-
particles were compared and the results indicated that OVA- and poly
(I:C)-containing cationic liposomes were more potent than the other
nanoparticles and signiﬁcantly increased the IgG2a response compared
to OVA and poly(I:C) solutions (Du et al., 2017). In the present study,
we used the same liposome composition to study whether co-en-
capsulation of antigen and immune modulator is the essential factor for
increased IgG2a levels. To investigate this, we co-encapsulated DT and
poly(I:C) or encapsulated them individually in liposomes and studied
the IgG (subtype) response following hollow microneedle-mediated
intradermal vaccination. The results showed that liposomal formula-
tions containing both DT and poly(I:C), induced higher IgG2a titers
than those induced by DT/poly(I:C) solutions, no matter whether only
one ingredient or both of them were encapsulated in liposomes. Fur-
thermore, DT and poly(I:C) that were both individually encapsulated in
liposomes induced similar IgG2a titers compared to DT and poly(I:C)
co-encapsulated in liposomes.
The results of Lipo-DT-PIC are well in accordance with previously
reported results (Bal et al., 2011; Varypataki et al., 2016), showing that
the co-encapsulation of antigen and immune modulator in liposomes
can increase IgG2a responses and favor Th1 type immune responses
after intradermal delivery by using a hypodermic needle. This may be
caused by a liposome induced increase in the uptake of antigen and
adjuvant by antigen presenting cells, as the size of liposomes (smaller
than 200 nm) is favorable for uptake by dendritic cells (Benne et al.,
2016; Manolova et al., 2008; Oyewumi et al., 2010). Burke et al. ad-
ditionally showed that liposomes may facilitate the access of poly(I:C)
to cellular cytoplasm and up-regulate TLR signalling molecules and
NLRP3 inﬂammasome pathway (Burke et al., 2014). Furthermore, ca-
tionic liposomes may have a stronger interaction with the negatively
charged cell membrane due to the attractive electrostatic interaction
compared to negatively charged particles, which allows longer reten-
tion time on the cell surface and subsequently sustained release of an-
tigen and adjuvant (Foged et al., 2004; Giddam et al., 2012; Ma et al.,
2011). As shown in the release study, less than 50% of the encapsulated
DT or poly(I:C) was released within one month, indicating that lipo-
somes act as a reservoir and allow the sustained release of DT and poly
(I:C). The slow release maybe due to strong electrostatic interactions
between the antigen and adjuvant (negatively charged) and the lipo-
somes (positively charged) and the stability of a large fraction of the
liposomes during the study (as encapsulated DT and poly(I:C) cannot
pass intact phospholipid bilayers). One limiting factor of using cationic
liposome based formulations is that toxicity of cationic liposomes has
been reported in vitro in salmonid cell (Romoren et al., 2004) and in vivo
studies after intravenous delivery (Knudsen et al., 2015). Further stu-
dies are needed to investigate the safety of cationic liposomes after
intradermal delivery. Finally, several studies have indicated that the co-
processing of antigen and adjuvant by antigen presenting cells after
being taken up may be the reason for a higher IgG2a response (Bal
et al., 2011; Boks et al., 2015; Du et al., 2017). The delivery of antigen
and the triggering of TLR in the same dendritic cell may synergistically
induce a superior antigen presentation to T cells (Boks et al., 2015;
Schulz et al., 2005).
The results of Lipo-DT+PIC and DT+ Lipo-PIC are in line with our
previous study by Varypataki et al, who found that the mixture of an-
tigen-loaded liposomes and free poly(I:C) solution induced a similar
IFN-γ-producing CD4+ T cell response (Th1) as antigen and adjuvant
co-encapsulated liposomes after hypodermic needle-mediated in-
tradermal delivery (Varypataki et al., 2017). One explanation may be
that the negatively charged antigen and adjuvant mixed with the li-
posome formulation adhered to the surface of positively charged lipo-
somes after intradermal injection due to the electrostatic interaction. As
a result, most of the antigen and adjuvant were co-delivered into the
antigen presenting cells although they were not co-encapsulated in the
liposomes. The adsorption study supported our hypothesis, as most of
Fig. 4. DT-neutralizing antibody titers of mice. Results are shown for serum
collected before sacriﬁce (day 56) from the tail vein of mice. The neutralizing
antibody titers were measured by Vero-cell assay and the titers were expressed
as the log2 values of the highest serum dilution that protected the Vero cells
against diphtheria toxin. Bars represent mean ± SEM, n=8. *p < 0.05.
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the DT or poly(I:C) was found to adsorb on the surface of liposomes
after mixing in PBS. Therefore, the association of DT and poly(I:C) is
probably needed for the modulation of immune responses by liposomes.
In case of the Lipo-DT+Lipo-PIC formulation, we expect that these
two liposomes would repel each other due to their strong surface
charge. Indeed, the particle size and zeta potential of Lipo-DT+Lipo-
PIC were found to remain the same within 24 h after mixing in PBS
(data not shown). Nevertheless, Lipo-DT+Lipo-PIC induced similar
IgG2a responses as Lipo-DT-PIC. These results indicate that the in-
dividually encapsulated DT and poly(I:C) are as eﬃcient as the DT and
poly(I:C) co-encapsulated in the liposomes for activation of immune
system when administered intradermally. This may be explained by an
eﬃcient uptake of both Lipo-DT and Lipo-PIC by the same antigen
presenting cells. One possible approach to further investigate this is to
use confocal microscopy to study the fate of ﬂuorescently labeled li-
posomes and antigen/adjuvant following administration in vivo.
In order to produce liposomes loaded with the optimal ratio of an-
tigen/adjuvant with a high loading eﬃciency, optimization work needs
to be done. Our results clearly suggest that co-encapsulation of antigen
and adjuvant in liposomes may not be necessary for the use in in-
tradermal delivery. This might simplify the work for the development of
formulations. This may even be particularly beneﬁcial for developing
formulations that must contain multiple antigens and adjuvants, e.g.,
for personalized therapies of cancer patients (Grabbe et al., 2016). Such
formulations can be prepared by mixing diﬀerent liposomes loaded
with only antigen or only adjuvant. Furthermore, it may be interesting
to test whether our current ﬁndings also hold true for other nano-
particulate vaccine delivery systems.
Finally, the results of neutralizing antibody assay indicate that high
IgG2a titers did not contribute to the immunity against diphtheria,
which is in line with a previous study (Ding et al., 2009). The high
IgG2a titers may be more suitable for anti-viral immune responses
where a Th1 response is more desired (Cenna et al., 2008). Based on the
obtained results, it would be of interest to examine the T cell responses
(such as antigen speciﬁc T-cell proliferation and secretion of cytokines,
such as IFN-γ). This will provide more detailed information about the
mechanisms involved in the eﬀect of individual versus co-encapsulation
of antigen and poly(I:C) in liposomes on the immune responses.
5. Conclusion
Our results show that DT and poly(I:C) can be successfully en-
capsulated into cationic liposomes with a high loading eﬃciency. After
hollow microneedle-mediated intradermal vaccination, the antigen and
adjuvant encapsulated liposomes evoked a potent immune response and
shifted the IgG1/IgG2a balance more to the IgG2a direction. The
combination of DT-encapsulated and poly(I:C)-encapsulated liposomes
are able to simulate an equally strong IgG2a response compared to DT
and poly(I:C) co-encapsulated liposomes. These ﬁndings may have
implications for future design of liposomal formulations aiming for
modiﬁcation of immune response after intradermal delivery.
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